Publications
Montoya Perez I, Merisaari H, Jambor I, Ettala O, Taimen P, Knaapila J, Kekki H, Khan FL, Syrjälä E, Steiner A, Syvänen KT, Verho J, Seppänen M, Rannikko A, Riikonen J, Mirtti T, Lamminen T, Saunavaara J, Falagario U, Martini A, Pahikkala T, Pettersson K, Boström PJ, Aronen HJ. Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. Journal of magnetic resonance imaging 2021
Anttinen M, Mäkelä P, Viitala A, Nurminen P, Suomi V, Sainio T, Saunavaara J, Taimen P, Sequeiros RB, Boström PJ. Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results. European urology open science 22:79-87, 2020
Blomqvist M, Koskinen I, Löyttyniemi E, Mirtti T, Boström PJ, Taimen P. Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. Scientific reports 11:13684, 2021
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, Mertens LS, Boevé ER, Neuzillet Y, Burger M, Pouessel D, Trombetta C, Wullich B, van der Kwast TH, Hartmann A, Allory Y, Lotan Y, Shariat SF, Zuiverloon TCM, Mir MC, van Rhijn BWG. Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival. World Journal of Urology 2021
Viitala A, Anttinen M, Wright C, Virtanen I, Mäkelä P, Hovinen T, Sainio T, Saunavaara J, Taimen P, Blanco RS, Boström PJ. MRI-guided transurethral ultrasound ablation for BPH: 12-month clinical outcomes of a phase I study. BJU International 2021 (epub)
Leo P, Janowczyk A, Elliott R, Janaki N, Bera K, Shiradkar R, Farré X, Fu P, El-Fahmawi A, Shahait M, Kim J, Lee D, Yamoah K, Rebbeck TR, Khani F, Robinson BD, Eklund L, Jambor I, Merisaari H, Ettala O, Taimen P, Aronen HJ, Boström PJ, Tewari A, Magi-Galluzzi C, Klein E, Purysko A, Nc Shih N, Feldman M, Gupta S, Lal Boström Peter J., Madabhushi A. Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. NPJ Precision oncology 3:35, 2021
Mattila KE, Laajala TD, Tornberg SV, Kilpeläinen TP, Vainio P, Ettala O, Boström PJ, Nisen H, Elo LL, Jaakkola PM. A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. Scientific Reports 11:8650, 2021
Malaspina S, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. European journal of nuclear medicine and molecular imaging 2021 (epub)
Malaspina S, Anttinen M, Taimen P, Jambor I, Sandell M, Rinta-Kiikka I, Kajander S, Schildt J, Saukko E, Noponen T, Saunavaara J, Dean PB, Sequeiros RB, Aronen HJ, Kemppainen J, Seppänen M, Boström PJ, Ettala O. Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. European journal of nuclear medicine and molecular imaging 8(9):2951-2959, 2021
Körner SK, Dreyer T, Haug ES, Jerlström T, Boström PJ, Gudjonsson S, Jensen JB. Which data are available in central registries on bladder cancer patients in the five Nordic countries. Scandinavian journal of urology 55:135-141, 2021
Mäkelä P, Anttinen M, Suomi V, Steiner A, Saunavaara J, Sainio T, Horte A, Taimen P, Boström P, Blanco Sequeiros R. Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer. Acta Radiologica 2020 (epub)
Ecke TH, Kiani A, Schlomm T, Friedersdorff F, Rabien A, Jung K, Kilic E, Boström P, Tervahartiala M, Taimen P, Gleichenhagen J, Johnen G, Brüning T, Koch S, Roggisch J, Wirtz RM. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RTqPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy. International journal of molecular sciences 21:7420, 2020
Seikkula H, Hirvonen E, Kaipia A, Boström PJ, Malila N, Pitkäniemi J. Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. Cancer Epidemiology 69:101807, 2020
Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Fossati N, Martini A, Cucchiara V, Picker W, Haug E, Ratnani P, Haines K, Lewis S, Sujit N, Selvaggio O, Sanguedolce F, Macarini L, Cormio L, Nordström T, Tewari A, Briganti A, Boström PJ, Carrieri G. Combined Boström Peter J. Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). European urology oncology 21:S2588-9311, 2020
Nason GJ, Jewett MAS, Bostrom PJ, Goldberg H, Hansen AR, Bedard PL, Sturgeon J, Warde P, Chung P, Anson-Cartwright L, Sweet J, Atenafu EG, O’Malley M, Hamilton RJ. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. European urology oncology 4:289-296, 2021
Anttinen M, Mäkelä P, Nurminen P, Yli-Pietilä E, Suomi V, Sainio T, Saunavaara J, Taimen P, Blanco Sequeiros R, Boström PJ. Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer. Scandinavian journal of urology 54:481-486, 2020
Falagario U, Jambor I, Taimen P, Syvänen KT, Kähkönen E, Merisaari H, Montoya Perez I, Knaapila J, Steiner A, Verho J, Tewari A, Aronen HJ, Carrieri G, Boström PJ, Ettala O. Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multiinstitutional external validation study. World journal of urology Urol. 9:1879-1887, 2020
Hiremath A, Shiradkar R, Merisaari H, Prasanna P, Ettala O, Taimen P, Aronen HJ, Boström PJ, Jambor I, Madabhushi A. Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps. European radiology 31:379-391, 2020
van Rhijn BWG, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, van der Heijden MS, Jewett MAS, Marquez M, Stoehr R, Zlotta AR, Eckstein M, Soorojebally Y, Roshani H, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, Wullich B, van der Kwast TH, Malats N, Hartmann A, Allory Y, Zuiverloon TCM. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? European Urology 78:682-687, 2020
Valta M, Ylä-Pelto J, Lan Y, Kähkönen T, Taimen P, Boström PJ, Ettala O, Khan S, Paulin N, Elo LL, Koskinen PJ, Härkönen P, Tuomela J. Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer. Translational andrology and urology 9:1120-1134, 2020
Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ. A Prospective Comparison of 18F-prostate specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). European urology oncology 13:S2588-9311, 2020
Movahedi P, Merisaari H, Perez IM, Taimen P, Kemppainen J, Kuisma A, Eskola O, Teuho J, Saunavaara J, Pesola M, Kähkönen E, Ettala O, Liimatainen T, Pahikkala T, Boström P, Aronen H, Minn H, Jambor I. Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. Scientific Reports 10:9407, 2020
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators1. Oral Relugolix for AndrogenDeprivation Therapy in Advanced Prostate Cancer. New England Journal of medicine. 382:2187 2196, 2020 (Boström Peter J. 1st investigator in the trial)
Knaapila J, Jambor I, Ettala O, Taimen P, Verho J, Perez IM, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. European urology Focus 7522-531, 2021
Seikkula H, Boström PJ, Seppä K, Pitkäniemi J, Malila N, Kaipia A. Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation. BMC Urology 20:25, 2020
Knaapila J, Autio V, Jambor I, Ettala O, Verho J, Kiviniemi A, Taimen P, Perez IM, Aronen HJ, Syvänen KT, Boström PJ. Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naïve men. Scandinavian journal of urology 54:7-13, 2020
Ettala O, Malaspina S, Tuokkola T, Luoto P, Löyttyniemi E, Boström PJ, Kemppainen J. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. European journal of nuclear medicine and molecular imaging 47:665-673, 2020
Seikkula H, Kaipia A, Hirvonen E, Rantanen M, Pitkäniemi J, Malila N, Boström PJ. Vasectomy and the risk of prostate cancer in a Finnish nationwide population-based cohort. Cancer Epidemiology 20:25, 2019
Perez IM, Jambor I, Kauko T, Verho J, Ettala O, Falagario U, Merisaari H, Kiviniemi A, Taimen P, Syvänen KT, Knaapila J, Seppänen M, Rannikko A, Riikonen J, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Pahikkala T, Boström PJ, Aronen HJ. Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials). Journal of magnetic resonance imaging 51:1556-1567, 2019
Merisaari H, Taimen P, Shiradkar R, Ettala O, Pesola M, Saunavaara J, Boström PJ, Madabhushi A, Aronen HJ, Jambor I. Repeatability of radiomics and machine learning for DWI: Short-term repeatability study of 112 patients with prostate cancer. Magnetic resonance in medicine 83:2293-2309, 2019
Khan MFL, Soikkeli M, Routila E, Krannila S, Terävä J, Taimen P, Boström PJ, Pettersson K. Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free ProstateSpecific Antigen. Journal of applied laboratory medicine 3:1014-1021, 2019
Montoya Perez I, Jambor I, Pahikkala T, Airola A, Merisaari H, Saunavaara J, Alinezhad S, Väänänen RM, Tallgrén T, Verho J, Kiviniemi A, Ettala O, Knaapila J, Syvänen KT, Kallajoki M, Vainio P, Aronen HJ, Pettersson K, Boström PJ, Taimen P. Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine-Learning Techniques.Journal of magnetic resonance imaging 51:1540-1553, 2019
Kaikkonen E, Ettala O, Nikulainen I, Taimen P, Lehtinen I, Boström PJ, Kellokumpu-Lehtinen PL, Schleutker J. ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castrationresistant Prostate Cancer.Anticancer research 39:5353-59, 2019
Anttinen M, Mäkelä P, Suomi V, Kiviniemi A, Saunavaara J, Sainio T, Horte A, Eklund L, Taimen P, Sequeiros RB, Boström PJ. Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer.Scandinavian journal of urology 26: 1-8, 2019
Klén R, Salminen AP, Mahmoudian M, Syvänen KT, Elo LL, Boström PJ. Prediction of complication related death after radical cystectomy for bladder cancer with machine learning methodology. Scandinavian journal of urology 25: 1-7, 2019
Knaapila J, Jambor I, Perez IM, Ettala O, Taimen P, Verho J, Kiviniemi A, Pahikkala T, Merisaari H, Lamminen T, Saunavaara J, Aronen HJ, Syvänen KT, Boström PJ. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study.European urology oncology 3:648-656, 2019
Ettala OO, Saaresranta T, Syvänen KT, Kaipia AJ, Vahlberg TJ, Aarnio PT, Boström PJ, Korhonen PE. Decreased forced expiratory volume in first second is associated with erectile dysfunction in apparently healthy men. A preliminary study. International journal of impotence research 32:420-425, 2019
Anttinen M, Yli-Pietilä E, Suomi V, Mäkelä P, Sainio T, Saunavaara J, Eklund L, Blanco Sequeiros R, Taimen P, Boström PJ. Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells.International journal of hyperthermia 36:915-925, 2019. DOI: 10.1080/02656736.2019.1652773
Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A; FinnProstate Group. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.European Urology 76:586-76, 2019
Toivonen J, Montoya Perez I, Movahedi P, Merisaari H, Pesola M, Taimen P, Boström PJ, Pohjankukka J, Kiviniemi A, Pahikkala T, Aronen HJ, Jambor I. Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization. PLoS One, 8:e0217702, 2019
Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, Kaipio K, Rantala J, Albanese C, Poutanen M, Taimen P. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells.European Urology 76,430-4, 2019
Sell V, Ettala O, Montoya Perez I, Järvinen R, Pekkarinen T, Vaarala M, Seppänen M, Liukkonen T, Marttila T, Aaltomaa S, Kaasinen E, Boström PJ. Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. World journal of urology 38:1001-1007, 2019
Jambor I, Verho J, Ettala O, Knaapila J, Taimen P, Syvänen KT, Kiviniemi A, Kähkönen E, Perez IM, Seppänen M, Rannikko A, Oksanen O, Riikonen J, Vimpeli SM, Kauko T, Merisaari H, Kallajoki M, Mirtti T, Lamminen T, Saunavaara J, Aronen HJ, Boström PJ. Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine 3:e1002813, 2019
Saarinen I, Jambor I, Kim M, Kuisma A, Kemppainen J, Merisaari H, Eskola O, Koskenniemi AR, Perez IM, Boström P, Taimen P, Minn H. Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.European journal of nuclear medicine and molecular imaging research. 31:50, 2019
Pietilä M, Sahgal P, Peuhu E, Jäntti NZ, Paatero I, Närvä E, Al-Akhrass H, Lilja J, Georgiadou M, Andersen OM, Padzik A, Sihto H, Joensuu H, Blomqvist M, Saarinen I, Boström PJ, Taimen P, Ivaska J. SORLA regulates endosomal trafficking and oncogenic fitness of HER2.Nature communications. 28:2340, 2019
Merisaari H, Jambor I, Ettala O, Boström PJ, Montoya Perez I, Verho J, Kiviniemi A, Syvänen K, Kähkönen E, Eklund L, Pahikkala T, Vainio P, Saunavaara J, Aronen HJ, Taimen P. IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy. Journal of magnetic resonance imaging, 50:1641-50, 2019
Malmström PU, Skaaheim Haug E, Boström PJ, Gudjónsson S, Bjerggaard Jensen J. Progress towards a Nordic standard for the investigation of hematuria: 2019. Scandinavian journal of urology 53:1-6, 2019
Koivisto M, Tervahartiala M, Kenessey I, Jalkanen S, Boström PJ, Salmi M. Cell-type specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis 12:40:84-92, 2019
Knaapila J, Gunell M, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Hakanen AJ, Boström PJ. Prevalence of Complications Leading to a Health Care Contact After Transrectal prostate biopsies: A prospective, controlled, multicenter study based on a selected Cohort.European Urology Focus 5: 443-448, 2019
Salminen AP, Koskinen I, Montoya Perez I, Hurme S, Murtola TJ, Vaarala MH, Nykopp TK, Seppänen M, Isotalo T, Marttila t, Levomäki L, Becker S, Anttinen M, Liukkonen T, Säily M, PogodinHannolainen D, Viitanen J, Palmberg C, Ottelin J, Sairanen J, Ettala OO, Boström PJ. Neoadjuvant chemotherapy does not increase morbidity of radical cystectomy – a 10-year retrospective nationwide study. European Urology Oncology 1:525-530 1, 2018
Knuuttila M, Mehmood A, Mäki-Jouppila J, Ryberg H, Taimen P, Knaapila J, Ettala O, Boström PJ, Ohlsson C, Venäläinen MS, Laiho A, Elo LL, Sipilä P, Mäkelä SI, Poutanen M. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. Endocrine Related Cancer 25:807-819, 2018
Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J. ANO7 is associated with aggressive prostate cancer. International journal of cancer 15:2479-2487, 2018
Montoya Perez I, Airola A, Boström PJ, Jambor I, Pahikkala T.Tournament leave-pair-out cross-validation for receiver operating characteristic analysis.Statisctical Methods in medical research 28:2975-91, 2019
Salminen A, Jambor I, Merisaari H, Ettala O, Virtanen J, Koskinen I, Veskimae E, Sairanen J, Taimen P, Kemppainen J, Minn H, Boström PJ. 11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial). Cancer Imaging, 2:25, 2018
Nurminen P, Ettala O, Seppänen M, Taimen P, Boström PJ, Kaipia A. Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment. BJU International 123:246-51, 2018
Knaapila J, Kallio H, Hakanen AJ, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Gunell M, Boström PJ. Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. BJU International 122:203-210, 2018
Ojalill M, Rappu P, Siljamäki E, Taimen P, Boström P, Heino J. The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis.Prostate 78:583-594, 2018
Ylönen O, Jyrkkiö S, Pukkala E, Syvänen K, Boström PJ. Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries.BJU International 122:384-393, 2018
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators1. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.New Enland journal of medicine 12:1408-1418, 2018. (Boström Peter J. 1st investigator in the trial)
Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T. New prostate cancer grade grouping system predicts survival after radical prostatectomy. Human pathology 75:159-166, 2018
Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, AnsonCartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. European Urology Focus 4:995-1001, 2018
Jambor I, Kuisma A, Kähkönen E, Kemppainen J, Merisaari H, Eskola O, Teuho J, Perez IM, Pesola M, Aronen HJ, Boström PJ, Taimen P, Minn H.. Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). European journal of nuclear medicine and molecular imaging 45:355-364, 2018
Seikkula HA, Kaipia AJ, Ryynänen H, Seppä K, Pitkäniemi JM, Malila NK, Boström PJ. The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland. International journal of cancer 142:891-898, 2017
Tervahartiala M, Taimen P, Mirtti T, Koskinen I, Ecke T, Jalkanen S, Boström PJ. Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. Scientific Reports 7:12682, 2017